Icare USA Completes Merger with CenterVue, Inc
Icare USA, Inc. today announced that it has completed its merger with CenterVue, Inc., after the acquisition of CenterVue by the Finnish Revenio Group Corporation in April 2019. As Icare USA, Inc., the merged companies join the original developer and global leader in handheld tonometry with a pioneer in highly automated ophthalmic imaging devices.
In March 2020, the two corporations were consolidated under a single management team. Coming from Icare, John Floyd is continuing as CEO and Holly Swain is Vice President of Medical Affairs. From CenterVue, Dave MacLellan now serves as Vice President of Sales, and Luca Zalunardo is Vice President of Marketing. John Hawley also joins the new team as Director of National and Government Accounts. The sales forces are remaining independent while leveraging interactions to be most effective in the market.
“We’ve undertaken this transition with great speed and excitement because the merger places our new combined team in a prime position in both the glaucoma and retina specialties,” said CEO John Floyd. “We have such a strong foundation of experience from both companies, not only in designing and manufacturing exceptional diagnostic technologies, but also in bringing new technologies to market and ensuring they thrive. Together we will achieve even more.”
Both Icare and CenterVue have well-known brands and patent-protected technology installed in clinics worldwide, offering physicians all the modern tools for diagnosis of glaucoma and other conditions. Icare USA, Inc., will have ample opportunities to expand the reach of these technologies under the umbrella of the Revenio Group Corporation, a publicly held international health technology group and global leader in ophthalmic devices.